van der Wouden CH et al (2017) Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin Pharmacol Ther 101(3):341–358

Article  PubMed  Google Scholar 

Abdullah-Koolmees H, van Keulen AM, Nijenhuis M, Deneer VHM (2021) Pharmacogenetics guidelines: overview and comparison of the DPWG, CPIC, CPNDS, and RNPGx guidelines. Front Pharmacol 11:595219. https://doi.org/10.3389/fphar.2020.595219

European Medicines Agency (EMA) (2009) Mandata, objectives and rules of procedure for the CHMP PG working party; Available from https://www.ema.europa.eu/en/documents/other/mandate-objectives-rules-procedure-chmp-pg-working-party_en.pdf. Accessed 25 Feb 2025

Ubiquitous Pharmacogenomics Consortium (2023) Ubiquitous pharmacogenomics (U-PGx): making actionable pharmacogenomic data and effective treatment optimization accessible to every European citizen. Available from: https://upgx.eu/. Accessed 25 Feb 2025

Swen JJ et al (2023) The PREPARE study: benefits of pharmacogenetic testing are unclear - Authors’ reply. Lancet 401(10391):1851–1852

Article  PubMed  Google Scholar 

Swen JJ et al (2023) A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet 401(10374):347–356

Article  CAS  PubMed  Google Scholar 

European Commission, The Heads of Medicines Agencies and the European Medicines Agency (EMA) (2024) Multi-stakeholder workshop on pharmacogenomics; Available from https://www.ema.europa.eu/en/events/joint-ec-hma-ema-multi-stakeholder-workshop-pharmacogenomics#documents-67807. Accessed 25 Feb 2025

de With M et al (2023) Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe. ESMO Open 8(2):101197

Article  PubMed  PubMed Central  Google Scholar 

Qureshi S et al (2022) Understanding the barriers and enablers of pharmacogenomic testing in primary care: a qualitative systematic review with meta-aggregation synthesis. Pharmacogenomics 23(2):135–154

Article  CAS  PubMed  Google Scholar 

Cicali EJ et al (2019) Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene-drug pairs across ambulatory care settings. Genet Med 21(10):2264–2274

Article  PubMed  PubMed Central  Google Scholar 

Cooper J et al (2024) Implementation of pharmacogenetic testing in pediatric oncology: barriers and facilitators assessment at eight Canadian academic health centres. Pharmacogenomics J 24(6):36

Article  CAS  PubMed  Google Scholar 

Apellaniz-Ruiz M et al (2024) Status of the implementation of pharmacogenetics in clinical practice in Spain: from regional to national initiatives. Drug Metab Pers Ther 39(4):183–199. https://doi.org/10.1515/dmpt-2024-0042

Bourgeois J, Costa E, Devos C, Hulstaert F, Luyten J, Ombelet S, Thiry N (2024) Pharmacogenetic tests in Belgium, in KCE Reports. Belgian Health Care Knowledge Center (KCE); Available from https://kce.fgov.be/sites/default/files/2024-05/KCE382_Pharmacogenetic_tests_in_Belgium.pdf. Accessed 25 Feb 2025

Casneuf V et al (2022) Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur). Acta Clin Belg 77(2):346–352

Article  CAS  PubMed  Google Scholar 

Cervantes A et al (2023) Metastatic colorectal cancer: esmo clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 34(1):10–32

Article  CAS  PubMed  Google Scholar 

Byrne RA et al (2023) 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 44(38):3720–3826

Article  CAS  PubMed  Google Scholar 

Pereira NL et al (2024) CYP2C19 Genetic testing for oral P2Y12 inhibitor therapy: a scientific statement from the American heart association. Circulation 150(6):e129–e150

Article  CAS  PubMed  Google Scholar 

European Medicines Agency (EMA) (2020) EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. Available from https://www.ema.europa.eu/en/documents/referral/fluorouracil-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing_en.pdf. Accessed 25 Feb 2025

Federal Agency for Medicines and Health Products (FAMHP) (2019) 5-fluorouracil and capecitabine - recommendations on deficiency of dihydropyrimidine dehydrogenase (DPD). Available from: https://www.fagg.be/nl/news/flash_vig_news_5_fluorouracil_en_capecitabine_aanbevelingen_bij_deficientie_van. Accessed 25 Feb 2025

National Institute for Health and Care Excellence (NICE) (2019) Crohn’s disease management (NG129), Available from https://www.nice.org.uk/guidance/ng129. Accessed 25 Feb 2025

Lichtenstein GR et al (2018) ACG Clinical guideline: management of Crohn’ disease in adults. Am J Gastroenterol 113(4):481–517

Article  PubMed  Google Scholar 

Haidar CE et al (2022) Advancing pharmacogenomics from single-gene to preemptive testing. Annu Rev Genomics Hum Genet 23:449–473

Article  CAS  PubMed  PubMed Central  Google Scholar 

McDermott JH et al (2024) Pre-emptive pharmacogenetic testing in the acute hospital setting: a cross-sectional study. QJM hcae200. https://doi.org/10.1093/qjmed/hcae200

The UK Clinical Study Registry (2024) Study to assess the rollout of a genetic-guided prescribing service in UK General Practice. Available from https://www.isrctn.com/ISRCTN15390784. Accessed 25 Feb 2025

Blagec K et al (2022) Pharmacogenomics decision support in the U-PGx project: results and advice from clinical implementation across seven European countries. PLoS One 17(6):e0268534

Article  CAS  PubMed  PubMed Central  Google Scholar 

Royal College of Physicians and British Pharmacological Society (2022) Personalised prescribing: using pharmacogenomics to improve patient outcomes. Report of a working party. London: RCP and BPS, 2022. Available from https://www.bps.ac.uk/getmedia/b43a3dca-1bbf-4bff-9379-20bef9349a8c/Personalised-prescribing-full-report.pdf.aspx. Accessed 25 Feb 2025

National Institute for Health and Care Excellence (2024) CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack. Available from https://www.nice.org.uk/guidance/dg59. Accessed 25 Feb 2025

Edris A et al (2021) Pharmacogenetics in clinical practice: current level of knowledge among Flemish physicians and pharmacists. Pharmacogenomics J 21(1):78–84

Article  CAS  PubMed  Google Scholar 

Haute Autorité de Santé (HAS) (2023) Méthodes de recherche d’un déficit en dihydropyrimidine deshydrogénase visant à prévenir certaines toxicités sévères associées aux traitements incluant une fluoropyrimidine (5-fluorouracile ou capécitabine) Available from https://www.has-sante.fr/jcms/c_2891090/fr/methodes-de-recherche-d-un-deficit-en-dihydropyrimidine-deshydrogenase-visant-a-prevenir-certaines-toxicites-severes-associees-aux-traitements-incluant-une-fluoropyrimidine-5-fluorouracile-ou-capecitabine. Accessed 25 Feb 2025

Swiss Society for Clinical Pharmacology and Toxicology (SSCPT) (2023) Pharmacogenetic testing information. Available from: https://sscpt.ch/en/pharmacogenetics_spt/swiss_group_of_personalised_therapy_and_pharmacogenomics/pharmacogenetic_testing_information. Accessed 25 Feb 2025

Abad-Santos F et al (2024) Developments in pharmacogenetics, pharmacogenomics, and personalized medicine. Pharmacol Res 200:107061

Article  PubMed  Google Scholar 

Ministerial Decree of 4 September 2023 laying down the special criteria for the recognition of specialist physicians (including trainee services), for clinical pharmacology and pharmaceutical medicine (2023) Available from https://etaamb.openjustice.be/nl/ministerieel-besluit-van-04-september-2023_n2023045744.html. Accessed 25 Feb 2025

Agence de la Biomédecine (ABM) (2022) Rapport medical et scientifique de l’assistance médicale à la procreation et de la génétique humaine en France. Available from https://rams.agence-biomedecine.fr/.  Accessed 25 Feb 2025